Macrophage Therapeutics (MT) is developing novel targeted anti-inflammatory and immuno-oncology therapeutics based on its proprietary Activated Macrophage targeting platform.
MT is leveraging its unique CD206 receptor-based delivery system to deliver proven therapeutics in a more precise and targeted fashion. With binding affinities 10,000X today’s best antibodies MT’s approach eliminates off-target toxicity and increases the efficacy of proven therapeutic agents. MT’s CD206 targeting platform is already clinically established and being used in an FDA/EMEA approved radiopharmaceutical.
Company Details
- Founded
- 2015
- Address
- 560 Sylvan Ave, Englewood Cliffs,new Jersey 07632,united States
- co****@****etx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- macrophagetx.com
- Keywords
- Representative jobs.
- HQ
- Englewood Cliffs, New Jersey
Macrophage Therapeutics, Inc. Questions
Macrophage Therapeutics, Inc.'s website is macrophagetx.com
Macrophage Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/macrophagetherapeutics
Macrophage Therapeutics, Inc.'s industry is
Biotechnology Research
Macrophage Therapeutics, Inc.'s top competitors are
Armas Pharmaceuticals,
Bezwada Biomedical, Llc,
Spes Pharmaceuticals Inc.,
Stira Pharmaceuticals,
Salix Pharmaceuticals,
Linnaeus Therapeutics, Inc.,
Novarock Biotherapeutics Ltd,
Revision Therapeutics, Inc.,
Silo Pharma Inc.,
Hepion Pharmaceuticals.
Macrophage Therapeutics, Inc.'s support email address is contact@macrophagetx.com
Macrophage Therapeutics, Inc.'s categories are Biotechnology Research
Macrophage Therapeutics, Inc.'s founding year is 2015
